Inclusion Criteria:  Alive patients who attended the SOLIDARITY Finland remdesivir sub-study  Eligibility criteria for SOLIDARITY Finland remdesivir -study:  Inclusion criteria:  Adult patients, 18 years and older Laboratory-confirmed SARS-CoV-2 infection Admitted to the hospital ward or the intensive care unit (ICU) Patient provides written informed consent prior to initiation of the study OR close relative/legal representative provides written informed consent prior to initiation of the study according to the presumed will of the patient when patient is unable to give consent. No anticipated transfer within 72 hours to a non-study hospital  Exclusion Criteria:  Severe co-morbidity with life expectancy <3 months according to investigators assessment ASAT/ALAT > 5 times the upper limit of normal Acute co-morbidity within 7 days before inclusion such as myocardial infarction or unstable angina pectoris (not including troponin elevation due to infection) Pregnancy or breast feeding Any reason why, in the opinion of the investigators, the patient should not participate Subject participates in a potentially confounding drug or device trial during the course of the study Already receiving the study drug Renal failure (eGRF < 30 mL/min) or dialysis/continuous veno-venous hemofiltration